Kornimate/medical-research-clean huggingface dataset:
multimodal physical therapy with exercise in partial-thickness rotator cuff tears

Conditions: Partial Thickness Rotator Cuff Tear

Summary: the aim of this study is to investigate the early stage effectiveness of multimodal physical therapy with exercise in the conservative treatment of partial thickness rotator cuff tears.

although partial thickness rotator cuff tear prevalence is greater than those of full-thickness tear, most studies on conservative treatment are associated with full-thickness tears. in general, any physical therapy modality alone is not effective in the treatment of rotator cuff tears. it has been reported that multimodal physiotherapy may be more successful than monotherapy, but evidence in this regard is inadequate. therefore this observational prospective study aiming to investigate the effectiveness of physiotherapy in the treatment of rotator cuff tears was planned. the null hypothesis of this study is that multimodal physical therapy combined with exercise has no effect on pain and function in the treatment of partial thickness rotator cuff tears. the alternative hypothesis is the opposite. patients will be assessed by standardized measures in terms of pain and function (american shoulder and elbow surgeons standardized shoulder form: patient self report section), active range of motion (goniometric measurement) and quality of life (western ontario rotator cuff index) at baseline and first, third and 6th months of follow-up.

Eligibility criteria:
inclusion criteria: * symptomatic partial thickness rotator cuff tear verified with magnetic resonance imaging or ultrasound imaging * prescription of multimodal physical therapy with exercise by a clinician other than investigators prior to inclusion in the study * covered by the social security system * giving informed consent to include in the study exclusion criteria: * age of under 50 * full thickness rotator cuff tear * radicular pain * glenohumeral osteoarthritis * calcific tendonitis * adhesive capsulitis * history of physiotherapy in last 6 months * prior surgical treatment * contraindication to physical therapy and/or exercises

Keywords: partial thickness rotator cuff tear physical therapy
haploidentical hematopoietic cell transplantation for children with hematologic malignancies and myelodysplasia

Conditions: Myelodysplasia; Hematologic Malignancy

Summary: this is a phase i/ii study designed to evaluate the kinetics of hematopoietic reconstitution and the incidence of acute chronic gvhd after partially matched related donor hematopoietic cell transplantation using an αβtcr/cd19+ cell depleted graft.

less than 30% of patients undergoing hematopoietic cell transplantation (hct) will have an hla-matched sibling donor. there is a high likelihood of being unable to identify a perfect hla matched unrelated donor, and the time to procure the marrow if such a donor is available is generally \>3 months. an emerging body of literature suggests that related haploidentical hct with innovative graft engineering may provide equal, or possibly superior, outcomes to conventional unrelated donors. this protocol is designed to test the hypothesis that hct using an αβt cell / cd19+ b cell depleted graft from partially matched related donors will result in rapid, durable hematopoietic engraftment and rapid immune reconstitution with an acceptably low risk of severe acute and chronic gvhd.

Eligibility criteria:
inclusion criteria: * patient lacks an hla matched sibling donor. * meets criteria nonhematopoietic organ function according to nch bmt sop09. * if subjects have received a first hct, they must be eligible for a second hct if their disease has recurred. * high resolution hla and kir typing * the subject cannot have an active untreated infection. viremia by pcr analysis is not considered an active infection but may require immediate viral prophylaxis. patients with possible fungal infections must have had at least 2 weeks of appropriate anti- fungal therapy and be asymptomatic. * negative pregnancy test for females ≥11 years of age or post- menarche. * sexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the investigator. (non-childbearing potential defined as pre-menarche, greater than one year post-menopausal or surgically sterilized). * subjects must be ≤30 years at the time of consent. * signed consent by parent/guardian and assent if appropriate for subjects \< 18 years of age. signed consent by patient/subject if ≥18 years of age. exclusion criteria: * patient does not have a suitable donor who is willing and able (meets donor criteria). * patient has donor-specific anti-hla antibodies at the time of enrollment * patient reports a history of allergic reactions to murine protein donor eligibility: * the donor must be ≥18 years of age at the time of the informed consent conference. * the donor must be a related donor * the donor will be evaluated according to the current nch bmt sop 04 and must meet all criteria. * the donor must be able and willing to undergo g-csf mobilization and stem cell apheresis. * the patient does not have donor specific anti-hla antibodies
a survey on quetiapine extended-release tablets in patients with depression in bipolar disorder

Conditions: Depression; Bipolar Disorder

Summary: the purpose of this study is to evaluate the safety and effectiveness of quetiapine in actual clinical settings.

this is a post-marketing use-result survey study required for products in japan. the investigator will register the patient who have been taking this product for the first time within 14 days after the start of treatment (inclusive of the start day). for each of the registered patients (including withdrawals and dropouts), the investigator will enter the survey data on the case report form.

Eligibility criteria:
inclusion criteria: * patients with depressive symptoms of bipolar disorder * patients who have previously not been treated with quetiapine fumarate (immediate-release formulations of quetiapine fumarate and bipresso extended-release tablets) exclusion criteria: * none

Keywords: bipresso drug use-results survey quetiapine
effects of a periodic repetitive transcranial magenetic stimulation in parkinson disease

Conditions: Transcranial Magnetic Stimulation; Parkinson's Disease

Summary: previous studies have shown that repetitive transcranial magnetic stimulation(rtms) can improve clinical symptoms of parkinson's disease(pd). continuous theta-burst stimulation(ctbs) is a novel rtms protocol that produces physiological effects b acting on neurons in the brain, which can decrease the excitability of motor system. this study aims to explore the long-term effects of ctbs on improvement of movement symptoms in patients with pd.

this was a open-label clinical trial to assess the effects of a periodic repetitive transcranial magenetic stimulation in parkinson disease. participants were randomly assigned to the ctbs group and the control group on a 1:1 basis using age as a stratification factor. in the ctbs group, after baseline assessment, participants received ctbs treatment on the left supplementary motor area(sma) for 14 days, and symptoms were assessed on the second day after treatment. ten weeks after completion of assessment, a second ctbs session was performed, with all patients taking stable doses of antiparkinsonian medications. the control group only received drug intervention, and symptom assessment was conducted at weeks 13, 23 , 33 , and 43. to rule out the influence of medication on symptom assessment, all patients stopped taking medication for at least 12 hours before assessment.

Eligibility criteria:
inclusion criteria: * meet the chinese diagnostic criteria for parkinson's disease (2016 version); * age ≥ 40 years old; * stable use of medication for at least 2 weeks; * mmse score ≧ 24 points; * those who can cooperate to complete the experiment; (6) those who have not received rtms treatment in the past. exclusion criteria: * history or clinical symptoms of other serious mental illnesses (such as major depression, psychosis, or obsessive-compulsive disorder); * severe organic brain defects on t1 or t2 images; * history or unknown epilepsy cause of loss of consciousness; * head injury, stroke or other neurological disease; * immovable metal objects on or around the head; * history of drug abuse within the past 6 months.

Keywords: transcranial magnetic stimulation parkinson's disease
gore-tex propaten vascular graft study

Conditions: Peripheral Vascular Diseases

Summary: to demonstrate equivalence in patency performance of gore-tex propaten vascular grafts and thin walled gore-tex stretch vascular grafts in a peripheral bypass application to support a claim of substantial equivalence.


Eligibility criteria:
inclusion criteria: * patient requires primary above-knee bypass where the proximal anastomosis will be to the common femoral or proximal superficial femoral artery and the distal anastomosis will be the popliteal artery proximal to the medial head of the gastrocnemius; * patient has grade iii or iv occlusive vascular disease; * patient has a postoperative life expectancy greater than one year; * patient is at least 21 years of age; * patient is able to comply with all study requirements and be available for follow-up visits at 1 month, 6 months and 12 months post procedure; * patient is willing and able to provide written, informed consent. exclusion criteria: * patient had a previous bypass in the diseased extremity (below iliacs); * patient has known coagulation disorders including hypercoagulability; * patient has had any previous instance of heparin induced thrombocytopenia type 2 (hit-2) or has known hypersensitivity to heparin; * patient has an acute embolic arterial occlusion; * patient requires sequential extremity revascularizations or other procedures that require use of additional vascular grafts; * patient had percutaneous transluminal angioplasty to the implant site within the previous 30 days; * patient is in need of, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure; * patient has active infection in the region of graft placement; or * patient has an incomplete preoperative assessment (as outlined in this protocol) due to an emergency procedure, a traumatic injury or any other reason.
evaluating the effect of mirtazapine on anxiety in parkinson's disease patients

Conditions: Parkinson Disease; Anxiety

Summary: this study is a single-center, parallel and double-blind study in movement disorders clinic of shohadaye tajrish hospital. patients, researchers (physicians, outcome assessors) and data analysts are blinded. after assessing the inclusion and exclusion criteria's, patients who assigned the informed consent form, are randomly divided into control and treatment groups.patients in treatment or placebo groups respectively receive mirtazapine (15 mg) or placebo, once a day for 12 weeks. primary (anxiety) and secondary (depression, fatigue, sleep disorders, and quality of life) outcomes are evaluated at baseline, and after 4 and 12 weeks of treatments.


Eligibility criteria:
inclusion criteria: * men and women over 17 years old * patient with parkinson's disease according to ukpdsbb criteria * patient with mild/moderate parkinson's disease according to hoehn and yahr scale (hy score = 1-3) * self-report or clinical diagnosis of anxiety * patients who have signed informed consent to participate in the study. exclusion criteria: * pregnant and lactating women * parkinson's patients with onset of disease in less than 1 year * unstable medication for parkinson's disease during the last two weeks * parkinson's patients with dbs * patients with other neurodegenerative diseases like multiple system atrophy (msa), huntington's and etc. * patients with major depressive disorder * a history of using ssris, snris, benzodiazepines and β-blockers during the last 4 weeks * a history of using mao inhibitors * a history of alcohol and substance abuse * a history of acute stress during the last 3 months * a history of suicide * a history of cardiovascular diseases * a history of liver and or kidney disorders

Keywords: parkinson's disease anxiety mirtazapine
study of sildenafil in advanced heart failure.

Conditions: Congestive Heart Failure

Summary: despite advances in medical therapy for patients with heart failure, one-third of patients remain limited by fatigue and shortness of breath. our previous study concluded that one dose of sildenafil (viagra) lead to an improvement in heart pressure and exercise capacity. currently sildenafil is not fda approved for the treatment of heart failure. the purpose of this study is to determine if treatment with sildenafil for 12 weeks in patients with heart failure can improve exercise capacity and quality of life in people with heart failure.

this study will compare two groups of patients. one group will receive sildenafil and the other group will receive a placebo (a pill which looks like sildenafil, but contains no medication). patients will undergo a heart catheterization, echocardiogram and exercise stress test. patients will then take study medication for 12 weeks. a repeat heart catheterization, echocardiogram and exercise stress test will then be performed.

Eligibility criteria:
inclusion criteria: age \>18 years ejection fraction \<40% heart failure limited by fatigue and shortness of breath pulmonary artery hypertension exclusion criteria: patients taking the following medications: nitroglycerine pill/patch/paste, isordil, imdur, antifungal agents and certain antidepressants. patients with a history of optic neuropathy or unexplained visual impairment. patients with anemia. -

Keywords: exercise stress test
chemoradiotherapy plus immunotherapy followed by surgery for esophageal cancer

Conditions: Esophagus Cancer; Neoadjuvant Therapy

Summary: neoadjuvant chemoradiotherapy is recommended as standard therapy for resectable esophageal cancer. the recurrence rate after surgery following neoadjuvant chemoradiotherapy is about 35%. whether achieving pathological complete response after neoadjuvant chemoradiotherapy is significantly associated with recurrence after surgery. it is reported that immunotherapy combined with chemotherapy improved survival compared with chemotherapy alone in first line therapy of advanced esophageal cancer. we hypothesize that the addition of immunotherapy to neoadjuvant chemoradiotherapy is helpful to improving pathologic complete response and survival.


Eligibility criteria:
main inclusion criteria: * pathologically diagnosed as esophageal squamous cell carcinoma * initially diagnosed as thoracic esophageal cancer * resectable or potantially resectable * ii-iva according to ajcc 8th edition； * kps≥70 * adequate organ function
cognitive engagement and aging mind

Conditions: Age-related Cognitive Decline

Summary: the purpose of this research is to examine whether and to what extent training of different types of cognitive engagement will improve performance on fluid cognitive abilities that typically decline with age. the research covered by this protocol will use behavioral data that yield response latencies and accuracies of the untrained tasks, and brain activations in fmri tasks, to test specific hypotheses about neural plasticity and cognitive plasticity from these engagement techniques. hence, human subjects will be employed in an experiment lasting for 20 hours spanning over 2 months where they will either receive real-time strategy-based videogame training or crystallized intelligence training. in addition, long-term retention data will be obtained after 6 month post-training to investigate any long-term benefits.

the purpose of this research is to examine whether and to what extent training of different types of cognitive engagement will improve performance on fluid cognitive abilities that typically decline with age (such as, speed of information processing, working memory capacity, episodic memory, and executive functions). the research covered by this protocol will use behavioral data that yield response latencies and accuracies of the untrained tasks, and brain activations in fmri tasks, to test specific hypotheses about the extent of transfer, if any, and the underlying cognitive constructs that may be trained in the process. hence, human subjects will be employed in an experiment lasting for 20 hours spanning over 2 months where they will either receive real-time strategy-based videogame training or crystallized intelligence training. in addition, long-term retention data will be obtained after 6 month post-training to investigate any long-term benefits.

Eligibility criteria:
inclusion criteria: * right-handed * over 50 years of age * native or fluent english speaker * not color-blind * magnetic resonance imaging eligible * mini mental status examination score \>24 exclusion criteria: * left-handed or ambidextrous * younger than 50 * cannot distinguish colors during color blindness test * claustrophobia * metal artifact in body * over 300 lb * pacemaker * mmse score lower than 24 * history of stroke * history of substance or alcohol abuse * currently taking anti-psychotic or anti-depression medication
pharmacologic effects of darifenacin and tolterodine on cardiovascular parameters in healthy subjects

Conditions: Healthy

Summary: this study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older


Eligibility criteria:
inclusion criteria: * healthy males and females ≥ 50 years * body mass index equal to or greater than 18.5 kg/m2 and less than 35.0 kg/m2 exclusion criteria: * known or suspected allergy to tolterodine er or darifenacin or their components * subjects with irregular day and night patterns such as night shift workers * significant medical problems know to affect heart rate (ie., hypertension, hypotension, history of heart failure, history of pulmonary disease, etc.) * history of any malignancy within the past 5 years, with the exception of localized basal cell carcinoma of the skin * pregnant or nursing women * subjects with diseases such as urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, severe renal insufficiency, etc. other protocol-defined inclusion/exclusion criteria may apply

Keywords: heart rate, overactive bladder
a study to evaluate the efficacy of sage-217 in the treatment of adult participants with major depressive disorder (mdd)

Conditions: Depressive Disorder, Major

Summary: the purpose of this study to evaluate the efficacy of sage-217 in the treatment of participants with mdd.

this study was previously posted by sage therapeutics. in november 2023, sponsorship of the trial was transferred to biogen.

Eligibility criteria:
inclusion criteria: 1. participant with diagnosis of mdd as diagnosed by structured clinical interview for diagnostic and diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) clinical trial version \[scid-5-ct\], with symptoms that have been present for at least a 4-week period. 2. participant has a hamilton rating scale for depression (ham-d) total score ≥24 at screening and day 1 (prior to dosing). 3. participants taking antidepressants must have been taking these medications at the same dose for at least 60 days prior to day 1. participants who have stopped taking antidepressants within 60 days must have stopped for longer than 5 half-lives of the antidepressant prior to day 1. participants receiving psychotherapy must have been receiving therapy on a regular schedule for at least 60 days prior to day 1. 4. participant is willing to delay start of other antidepressant or antianxiety medications and any new pharmacotherapy regimens, including as-needed benzodiazepine anxiolytics and sleep aids, until after completion of the day 42 visit. exclusion criteria: 1. participant is currently at significant risk of suicide, as judged by the investigator, or has attempted suicide associated with the current episode of mdd. 2. participant has onset of the current depressive episode during pregnancy or 4 weeks postpartum, or the participant has presented for screening during the 6-month postpartum period. 3. participant has a body mass index (bmi) ≤18 or ≥45 kg/m\^2 at screening, which is subject to a broader evaluation of medical comorbidities. 4. participant has treatment-resistant depression, defined as persistent depressive symptoms despite treatment with adequate doses of antidepressants within the current major depressive episode (excluding antipsychotics) from two different classes for at least 4 weeks of treatment. 5. participant has a medical history of seizures, bipolar disorder, schizophrenia, and/or schizoaffective disorder. 6. participant has a history of mild, moderate, or severe substance use disorder (including benzodiazepines) diagnosed using dsm-5 criteria in the 12 months prior to screening. 7. participant is taking psychostimulants (eg, methylphenidate, amphetamine) or opioids, regularly or as-needed, at day -28.

Keywords: depression depressive disorder sage-217
exercise and diet program for schizophrenia patients who are taking atypical antipsychotic medications

Conditions: Schizophrenia

Summary: in this study the investigators will recruit patients with the diagnosis of schizophrenia that are taking atypical neuroleptics and that are willing to participate in an exercise and diet program. the investigators will measure weight and abdomen circumference.


Eligibility criteria:
inclusion criteria: * schizophrenia * atypical neuroleptics exclusion criteria: * medical illness preventing exercise

Keywords: schizophrenia weight gain atypical neuroleptics
diagnostic study of adrenal cortical function in children with septic shock

Conditions: Septic Shock

Summary: objectives: i. examine adrenal cortical function and the incidence of adrenal dysfunction in children with septic shock. ii. examine the mortality, length of stay in the picu, and incidence of multiorgan failure in children with adrenal dysfunction and septic shock.

protocol outline: patients undergo a corticotropin stimulation test within 8 hours of admission to the picu. blood samples for plasma cortisol and corticotropin levels are drawn at time 0 followed by corticotropin 1-24 iv. additional cortisol levels are drawn at 30 and 60 minutes. corticotropin is measured by immunoradiometric assay and cortisol is measured by radioimmunoassay. mean arterial blood pressure, heart rate, and respiratory rate are recorded at baseline and at 60 minutes. patients receive routine management for septic shock and multiple organ system failure.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- patients admitted to the picu with septic shock; hypotension (systolic blood pressure less than 2 standard deviations below age normal) plus 3 or more of the following: temperature greater than 38 or less than 36 degrees celsius; heart rate greater than 90th percentile for age; respiratory rate greater than 90th percentile for age; wbc greater than 12,000/mm3 or less than 4,000/mm3 or greater than 10% band forms; perfusion abnormalities including lactic acidosis, oliguria, or an acute alteration in mental status arterial or central venous catheter in place --prior/concurrent therapy-- at least one month since prior corticosteroids --patient characteristics-- renal: no nephrotic syndrome requiring glucocorticoids pulmonary: no asthma requiring glucocorticoids other: no condition requiring glucocorticoids (e.g., adrenal insufficiency); no uncontrolled diabetes mellitus; no prior adrenal dysfunction (plasma cortisol concentration less than 19 mcg/dl 30 and 60 minutes post corticotropin stimulation); no hypersensitivity to corticotropin

Keywords: immunologic disorders and infectious disorders rare disease sepsis septic shock